FALSE CLAIMS ACT
FALSE CLAIMS ACT
The 1863 False Claims Act (FCA) is a federal law that allows whistleblowers to report companies or individuals that are defrauding the U.S. government. A lawsuit filed under this statute, known as a Qui Tam case, is submitted directly to the federal court system; the whistleblower, known as the relator, is effectively suing the fraudulent company or individual on behalf of the Department of Justice. The government has the option of joining the plaintiff’s case against the fraudulent corporation or individual or decline to do so, leaving the relators free to proceed with the case in court on their own.
The federal government is the top money spender in the United States and contracts with thousands of companies to provide goods and services. This expenditure affects millions of citizens including patients who rely on health care services and prescription drugs paid for by Medicare and Medicaid, drivers who depend on the safe maintenance of highways and other aspects of our nation’s infrastructure, and American soldiers who depend on defense contractors to manufacture reliable body armor and dependable weapons. Since many of these contracts directly affect the safety and interests of U.S. taxpayers, many who are honest and brave enough often blow the whistle and bring these criminals to justice.
FALSE CLAIMS ACT WHISTLEBLOWER PROTECTIONS
The False Claims Act provides strong, comprehensive protections to whistleblowers who choose to come forward against corruption or fraud. The FCA’s Anti-Retaliation provision prohibits an employer from terminating, demoting or harassing any employee who has exposed corporate wrongdoing by filing a Qui Tam case. Employers who choose to ignore the law and retaliate against a whistleblower subject themselves to separate harsh retaliation lawsuits that entitle the relator to double backpay, reinstatement, and reimbursement for their litigation costs.
WHISTLEBLOWERS REWARD PROVISION
Under this law, the relator’s payment is determined as a percentage of the total amount recovered by the authorities following a successful case. The whistleblower’s reward can fall into two ranges (15% – 25% and 25% – 30%), depending on whether the government, respectively, joins or not their cases. In either situation, the final percentage awarded to the plaintiff is determined by how critical their privileged information was to the case’s ultimate success.
COMMON TYPES OF FRAUD
Common types of fraud that qualify as potential qui tam suits and are prosecuted under the False Claims Act include:
- Promoting prescription drugs for uses not approved by the FDA (off-label marketing)
- Bribing or paying kickbacks to obtain business
- Sale of adulterated (low quality, dangerously made, or harmful) medications
- Billing the authorities for services that were never performed
- Delivering defective or inferior goods paid for by federal funds
- Collusive bidding to secure government contracts
OUR SUCCESSES IN FCA WHISTLEBLOWER CASES
MCKESSON INFLATED PRICES
The pharmaceutical distributor paid $190 million to settle accusations of violating the FCA by falsely inflating information about the prices of several prescription medications, overbilling Medicaid for those drugs.
JOHNSON AND JOHNSON KICKBACKS
On November 4, 2013, Johnson & Johnson paid $2.2 billion to settle claims that it had illegally paid kickbacks as well as off-label marketed its antipsychotic drug Risperdal to the elderly and children.
Contact Us Today
The information submitted will be submitted to the law firm of Piacentile & Associates LLP d/b/a Whistleblowers International. This communication does not create an attorney-client relationship and is submitted only for the purpose of evaluating your claim to see if this is something we are able to help you with. By contacting us, you certify that you are a potential client making a bona fide inquiry about obtaining legal services to address a potential whistleblowing legal claim. Past results do not guarantee future outcomes. While this submission does not create an attorney-client relationship, all information submitted will be kept strictly confidential per legal ethics rules since this information is submitted in contemplation of a potential attorney-client relationship. No attorney-client relationship is formed until it is determined after evaluation with you that this is something we can take on and a retainer agreement is signed by you and the law firm of Piacentile & Associates LLP d/b/a Whistleblowers International. Please also understand that by submitting your information, there is no guarantee that we will contact you in response, as at any given time, there are only a limited number of claims we are able to take on and pursue. If we do not contact you within 3-business days of your submission, please reach out to another whistleblower law firm if you are interested in pursuing your matter.
Our Areas of Practice
Healthcare Fraud
Securities / Derivatives Fraud
Fraud Against the Government
Tax Fraud
Cryptocurrencies Fraud
Defense Contractor Fraud
Money Laundering
Foreign Corrupt Practices Act
DR. JOE’S CASES HAVE BEEN FEATURED IN:
COMMITTED TO GLOBAL TRANSPARENCY
SEC Whistleblower Anonymity Rules: Myths vs. Reality in 2026
What if the greatest barrier to your multi-million dollar recovery isn’t the complexity of the fraud you’ve uncovered, but the quiet fear that your…
What is FinCEN? The 2026 Guide to the Financial Crimes Enforcement Network
In 2026, reporting a single violation of the Bank Secrecy Act can now result in a whistleblower award exceeding $30 million. If you have uncovered…
How to Report Procurement Fraud: A 2026 Whistleblower’s Strategic Guide
In fiscal year 2025, the Department of Justice recovered over $6.8 billion in settlements and judgments under the False Claims Act, marking the…
SEC Whistleblower Reward Eligibility and Statute of Limitations: The 2026 Legal Guide
The greatest threat to your SEC whistleblower award isn’t the corporation’s legal team; it’s the calendar. While you might possess undeniable…
FCPA Whistleblower Lawyer: A 2026 Guide to Reporting Foreign Bribery
Reporting a multibillion-dollar foreign bribery scheme is often viewed as a career-ending risk, but in the current regulatory environment, it is…
Federal Whistleblower Rewards: 2026 Legal Guide
With over $2 billion awarded to individuals by the SEC since 2011, the financial incentive for exposing corporate misconduct via federal…
Reporting Pharmaceutical Fraud Anonymously: A 2026 Strategic Guide
Anonymity in the pharmaceutical industry isn’t just a safety precaution; it’s the most powerful tactical advantage a whistleblower can hold. You’ve…
Reporting Healthcare Fraud to the Government: A 2026 Whistleblower’s Guide
In fiscal year 2025, settlements and judgments under the False Claims Act reached a historic high of over $6.8 billion, proving that the government…
Reporting Trade Fraud: 2026 Whistleblower Reward Guide
In less than twelve months, the Department of Justice’s Trade Fraud Task Force has recovered over $1 billion from entities evading international…
Commodities Market Fraud Reporting: A Whistleblower’s Guide to Rewards and Protections
Did you know that a single whistleblower tip regarding commodities fraud resulted in a record-breaking $200 million award? This figure represents…
The information on this website is for general information purposes only. Nothing on this site should be taken as legal advice for any individual case or situation.
We do not accept cases in all jurisdictions. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers. Prior results do not guarantee a similar outcome. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship. While we will treat any information provided as privileged and confidential, you should understand that when you provide information about a potential case to us, we do not become your attorneys. We do not represent you until we have agreed to do so and a retainer has been signed by both of us. This information is not intended to create, and receipt or viewing does not constitute, an attorney-client relationship. This website may be considered attorney advertising in some states.
© 2024 All Rights Reserved.











